-Reuters
Needham Reiterates Buy on Trevi Therapeutics, Maintains $8 Price Target
Needham analyst Serge Belanger reiterates Trevi Therapeutics (NASDAQ:TRVI) with a Buy and maintains $8 price target.
Related Posts
Elon Musk’s Attorney Writes To Satya Nadella, Accuses Microsoft Of Unauthorized Twitter Data Use
Twitter has reportedly leveled accusations against Microsoft Corp. (NASDAQ:MSFT), claiming that the tech giant has been utilizing its…
E-Home Household Services Holdings Limited Signs New Property Cleaning Contracts With A Total Value Of Over RMB19 Million In Q4 Of 2023
E-Home Household Services Holdings Limited (NASDAQ:EJH) (the "Company" or "eHome"), an integrated home services provider in China, today announced that in the fourth quarter of 2023, the Company signed 27 new
Unitil Announces Its Board Of Directors Has Approved Several Corporate Organizational Changes, All Of Which Are Effective As Of May 1, 2023
Unitil Corporation ("Unitil" or the "Company") (NYSE:UTL) (unitil.com) today announced that its Board of Directors has approved several corporate organizational changes, all of which are effective as